Skip to main content
Clinical Trials/NL-OMON49487
NL-OMON49487
Not yet recruiting
Not Applicable

Metacognitive therapy for Generalized Anxiety Disorder in patients with a schizophrenia-spectrum disorder - MCT for GAD with schizophrenia-spectrum disorder

Parnassia Bavo Groep (Den Haag)0 sites9 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Parnassia Bavo Groep (Den Haag)
Enrollment
9
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Parnassia Bavo Groep (Den Haag)

Eligibility Criteria

Inclusion Criteria

  • 1\. Age between 18\-65;
  • 2\. primary diagnosis of schizophrenia\-spectrum disorder according to DSM\-5
  • 3\. A score of 10 or higher on the GAD\-7, a diagnostic screening list for GAD
  • 4\. A clinically significant degree of worrying, shown by a high score (\* 49\) on
  • the Penn State Worry Questionnaire
  • 5\. In case of intended radical changes in the field of pharmacotherapy,
  • patients can only enter the study if the dose is stable for at least one month.

Exclusion Criteria

  • Patients are excluded when:
  • 1\. they are unable or seem unable to give informed consent;
  • 2\. they don't sufficiently master the dutch language to undergo treatment
  • without an interpreter
  • 3\. there is alcohol or drug abuse that interferes with treatment
  • 4\. they have an IQ of 70 or below
  • 5\. they have an organic disorder

Outcomes

Primary Outcomes

Not specified

Similar Trials